BOSTON, April 30, 2019 — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include: Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögrens Giant[…]
December 18, 2018 – PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named OM1 as one of the most innovative Services of 2018. Founded in 2015, OM1 is a health outcomes and technology company leveraging big clinical data, standardized outcome measurement, and artificial intelligence[…]
November 15, 2018 —OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm. OM1’s Richard Gliklich and Michelle Leavy collaborated on the development of the measures and co-authored the publication. The work was funded by the Agency for Healthcare Research and Quality (AHRQ) through[…]
OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]
August 30, 2018 – 2:00 – 3:00 pm ET Registries continue to be a critical part of the real-world evidence equation, but over time they have become too trialized, too burdensome, and too separated from real clinical practice. Emerging methodologies, data digitization, and cognitive technologies have set the path for drastic changes needed to address[…]
